aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September

Loading news article.

aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September | WAPE

aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September

Article summary

Related companies

Analyzed by WAPE AI.

Comments —